CONTEXT: Fetuin-A is a hepatic secretory protein that binds the insulin receptor and inhibits insulin action in vitro. In prior cross-sectional studies in humans, higher fetuin-A levels were associated with insulin resistance. However, the longitudinal association of fetuin-A with incident type 2 diabetes mellitus is unknown. OBJECTIVE: To determine whether fetuin-A levels are associated with incident diabetes in older persons. DESIGN, SETTING, AND PARTICIPANTS: Observational study among 3075 well-functioning persons aged 70 to 79 years. In this case-cohort study, we retrospectively measured fetuin-A levels in baseline serum among 406 randomly selected participants without prevalent diabetes, and all participants who developed incident diabetes mellitus during a 6-year follow-up (to August 31, 2005). MAIN OUTCOME MEASURE: Incident diabetes mellitus. RESULTS: Incident diabetes developed in 135 participants (10.1 cases/1000 person-years). Participants with fetuin-A levels within the highest tertile (> 0.97 g/L) had an increased risk of incident diabetes (13.3 cases/1000 person-years) compared with participants in the lowest tertile (< or = 0.76 g/L) (6.5 cases/1000 person-years) in models adjusted for age, sex, race, waist circumference, body weight, physical activity, blood pressure level, fasting glucose level, high-density lipoprotein cholesterol concentration, triglyceride concentration, and C-reactive protein level (adjusted hazard ratio, 2.41; 95% confidence interval, 1.28-4.53; P = .007). The association was not affected by adipocytokine levels but was moderately attenuated by adjustment for visceral adiposity (adjusted hazard ratio of highest vs lowest tertile 1.72; 95% confidence interval, 0.98-3.05; P = .06). CONCLUSION: Among well-functioning older persons, serum fetuin-A is associated with incident diabetes, independent of other markers of insulin resistance.
CONTEXT: Fetuin-A is a hepatic secretory protein that binds the insulin receptor and inhibits insulin action in vitro. In prior cross-sectional studies in humans, higher fetuin-A levels were associated with insulin resistance. However, the longitudinal association of fetuin-A with incident type 2 diabetes mellitus is unknown. OBJECTIVE: To determine whether fetuin-A levels are associated with incident diabetes in older persons. DESIGN, SETTING, AND PARTICIPANTS: Observational study among 3075 well-functioning persons aged 70 to 79 years. In this case-cohort study, we retrospectively measured fetuin-A levels in baseline serum among 406 randomly selected participants without prevalent diabetes, and all participants who developed incident diabetes mellitus during a 6-year follow-up (to August 31, 2005). MAIN OUTCOME MEASURE: Incident diabetes mellitus. RESULTS: Incident diabetes developed in 135 participants (10.1 cases/1000 person-years). Participants with fetuin-A levels within the highest tertile (> 0.97 g/L) had an increased risk of incident diabetes (13.3 cases/1000 person-years) compared with participants in the lowest tertile (< or = 0.76 g/L) (6.5 cases/1000 person-years) in models adjusted for age, sex, race, waist circumference, body weight, physical activity, blood pressure level, fasting glucose level, high-density lipoprotein cholesterol concentration, triglyceride concentration, and C-reactive protein level (adjusted hazard ratio, 2.41; 95% confidence interval, 1.28-4.53; P = .007). The association was not affected by adipocytokine levels but was moderately attenuated by adjustment for visceral adiposity (adjusted hazard ratio of highest vs lowest tertile 1.72; 95% confidence interval, 0.98-3.05; P = .06). CONCLUSION: Among well-functioning older persons, serum fetuin-A is associated with incident diabetes, independent of other markers of insulin resistance.
Authors: Suresh T Mathews; Sanjay Rakhade; Xiaohua Zhou; Graham C Parker; Donald V Coscina; George Grunberger Journal: Biochem Biophys Res Commun Date: 2006-09-25 Impact factor: 3.575
Authors: Joachim H Ix; Glenn M Chertow; Michael G Shlipak; Vincent M Brandenburg; Markus Ketteler; Mary A Whooley Journal: Nephrol Dial Transplant Date: 2006-04-27 Impact factor: 5.992
Authors: Norbert Stefan; Anita M Hennige; Harald Staiger; Jürgen Machann; Fritz Schick; Stefan M Kröber; Fausto Machicao; Andreas Fritsche; Hans-Ulrich Häring Journal: Diabetes Care Date: 2006-04 Impact factor: 19.112
Authors: Joachim H Ix; Michael G Shlipak; Vincent M Brandenburg; Sadia Ali; Markus Ketteler; Mary A Whooley Journal: Circulation Date: 2006-03-27 Impact factor: 29.690
Authors: Sharon M Moe; Martina Reslerova; Markus Ketteler; Kalisha O'neill; Danxia Duan; Jacob Koczman; Ralf Westenfeld; Willi Jahnen-Dechent; Neal X Chen Journal: Kidney Int Date: 2005-06 Impact factor: 10.612
Authors: Joachim H Ix; Glenn M Chertow; Michael G Shlipak; Vincent M Brandenburg; Markus Ketteler; Mary A Whooley Journal: Circulation Date: 2007-05-07 Impact factor: 29.690
Authors: Benjamin D Parker; Leon J Schurgers; Vincent M Brandenburg; Robert H Christenson; Cees Vermeer; Markus Ketteler; Michael G Shlipak; Mary A Whooley; Joachim H Ix Journal: Ann Intern Med Date: 2010-05-18 Impact factor: 25.391
Authors: Todd H Driver; Ronit Katz; Joachim H Ix; Jared W Magnani; Carmen A Peralta; Chirag R Parikh; Linda Fried; Anne B Newman; Stephen B Kritchevsky; Mark J Sarnak; Michael G Shlipak Journal: Am J Kidney Dis Date: 2014-03-18 Impact factor: 8.860
Authors: Monik C Jiménez; Qi Sun; Markus Schürks; Frank B Hu; Joann E Manson; Kathryn M Rexrode Journal: Clin Chem Date: 2013-10-29 Impact factor: 8.327
Authors: Gail A Laughlin; Linda K McEvoy; Elizabeth Barrett-Connor; Lori B Daniels; Joachim H Ix Journal: Clin Endocrinol (Oxf) Date: 2014-01-07 Impact factor: 3.478
Authors: Konstantinos Kantartzis; Andreas Peter; Fausto Machicao; Jürgen Machann; Silvia Wagner; Ingmar Königsrainer; Alfred Königsrainer; Fritz Schick; Andreas Fritsche; Hans-Ulrich Häring; Norbert Stefan Journal: Diabetes Date: 2009-08-03 Impact factor: 9.461